British drugmaker GlaxoSmithKline said that its IL-5 drug Nucala has received the US Food and Drug Administration’s approval for kids between 6 and 11 years old. Nucala, which is an at-home injection through the prefilled syringe, could help asthmatic children with  a better quality of life, said GSK’s US senior medical lead Tom Corbridge.  This drug was approved as an add-on maintenance therapy for kids and adults 12 years and older with SEA back in 2015 and it was the first IL-5 drug to win marketing approval in severe asthma.